Euroland - Welcome Page

TimeZone

Currency

Language

HOME

ABOUT US MY EUROLAND USERS’ PAGE CORPORATE SITES CONTACT US SITE OVERVIEW LINKS

Press releases - Corporate Sites

Select Stock Market:

All	Abu Dhabi	Amsterdam	BATS	Bombay	Brussels	Burgundy	Chi-X	Copenhagen	Dubai	Dublin	Frankfurt
Hanoi	Helsinki	HoChiMinh	Hong Kong	Iceland	Lisbon	London	Madrid	Milan	Moscow	Moscow Classica
Nasdaq	NSE (India)	NYSE	NYSE MKT	Oslo	Paris	Riga	Shanghai	Stockholm	Tallinn	Tokyo
Toronto	TSX Venture	Tunis	USOTC	Warsaw	Vienna	Vilnius	XETRA	Zurich

Select Period:						Order by:
All	Today	Yesterday	Last week	Last month		Date	Company

2014-01-05
EISAI CO., LTD. : Innovative Metastatic Breast Cancer Treatment Halaven® (Eribulin) Recieves Reimbursement Approval in the Czech Republic

2014-01-05
EISAI CO., LTD. : Life-extending Metastatic Breast Cancer Treatment Now Available in the Republic of Ireland

2014-01-15
EISAI CO., LTD. : New First-in-class Epilepsy Treatment Fycompa® (perampanel) Launches in Spain

2014-01-21
EISAI CO., LTD. : European Commission Grants Orphan Drug Status to Eisai´s Amatuximab for the Treatment of Malignant Mesothelioma

2014-01-22
EISAI CO., LTD. : Zonegran® (zonisamide) Reimbursed in Switzerland as Monotherapy Treatment for Adults With Newly Diagnosed Partial Epilepsy

2014-02-02
EISAI CO., LTD. : Once-daily Epilepsy Treatment Zebinix® (Eslicarbazepine Acetate) Now Available with Full Reimbursement in Finland

2014-02-03
EISAI CO., LTD. : Phase III Select Trial of Lenvatinib Meets Primary Endpoint of Improved Progression Free Survival in the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

2014-02-09
EISAI CO., LTD. : Fycompa® (Perampanel) to be Resubmitted Early to German Federal Joint Committee (G-BA) for Additional Benefit Assessment

2014-02-18
EISAI CO., LTD. : Epilepsy Treatment Zonegran® (Zonisamide) Receives Reimbursement in Spain as Monotherapy for Adults and Adjunctive Therapy for Children and Adolescents

2014-03-09
EISAI CO., LTD. : Zonegran® (Zonisamide) Approved for Use in Children and Adolescents by Scottish Medicines Consortium (SMC)

2014-04-06
EISAI CO., LTD. : Halaven® (Eribulin) Now Commercially Available in Lebanon for the Treatment of Metastatic Breast Cancer

2014-04-21
EISAI CO., LTD. : Zonegran® (Zonisamide) Well Tolerated in Long-term Treatment of Children with Partial Epilepsy

2014-04-27
EISAI CO., LTD. : Zonegran® (Zonisamide) Monotherapy Now Available in Russia for Adults With Newly Diagnosed Epilepsy

2014-05-11
EISAI CO., LTD. : Eisai Resubmits Fycompa® (perampanel) to German Federal Joint Committee for Additional Benefit Assessment

2014-05-11
EISAI CO., LTD. : Italian Medicines Agency (AIFA) Approves the Reimbursement of Zebinix® (eslicarbazepine acetate) as an Adjunctive Treatment to be Administered Once Daily in the Treatment of Partial Epilepsy in Adults

2014-05-12
EISAI CO., LTD. : New First-in-Class Epilepsy Treatment Fycompa® (Perampanel) Launches in the Netherlands

2014-05-14
EISAI CO., LTD. : Study Shows Fycompa® (perampanel) Provides Sustained Seizure Control for People Living With Epilepsy

2014-05-15
EISAI CO., LTD. : Eisai Highlights New Research at 50th ASCO Annual Meeting

2014-05-16
EISAI CO., LTD. : Italian Medicines Agency (AIFA) approves the reimbursement of Zebinix® (eslicarbazepine acetate) as a once daily adjunctive treatment of partial onset seizures in adults

2014-05-28
EISAI CO., LTD. : Study Shows Fycompa® (Perampanel)Provides Sustained Seizure Control for People Living With Refractory Epilepsy

20	40	60	80	100	120	140	160	180	200	220	240	260	280	300	320	340	360	380	400
420

2014

Back